JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB30679

Anti-GIP 抗体 [04]

Anti-GIP antibody [04]

5

(4 Reviews)

|

(9 Publications)

Mouse Monoclonal GIP antibody. Suitable for IHC-P and reacts with Human samples. Cited in 9 publications. Immunogen corresponding to Synthetic Peptide within Human Gastric inhibitory polypeptide.

別名を表示する

Gastric inhibitory polypeptide, GIP, Glucose-dependent insulinotropic polypeptide, Incretin hormone

2 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GIP antibody [04] (AB30679)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GIP antibody [04] (AB30679)

ab30679 at 1/100 staining GIP in human small intestine by IHC-P.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GIP antibody [04] (AB30679)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GIP antibody [04] (AB30679)

ab30679 at 1/100 staining GIP in human duodenum by IHC-P.

Key facts

宿主種

Mouse

クローン性

Monoclonal

クローン番号

04

アイソタイプ

IgG1

軽鎖のタイプ

kappa

キャリアフリー

No

交差種

Human

アプリケーション

IHC-P

applications

免疫原

Synthetic Peptide within Human Gastric inhibitory polypeptide. The exact immunogen used to generate this antibody is proprietary information.

P09681

特異性

Ab30679 recognises GIP. It cross reacts up to 10% with PACAP and GLP2 but <0.1% with glucagon, GLP1 or VIP.

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol." } } }
style
left-column

製品の詳細

Fusion partner: SP2/mIL6.
style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.097% Sodium azide Constituents: PBS, 0.87% Sodium chloride
出荷温度
Blue Ice
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

The Glucose-dependent Insulinotropic Polypeptide (GIP) also known as gastric inhibitory polypeptide is a hormone with a molecular mass around 5 kDa. It is a 42-amino acid peptide secreted by the K cells in the duodenum and jejunum of the small intestine. This protein interacts with the GIP receptor which is found in various tissues including pancreatic beta cells adipose tissue and the central nervous system. Researchers utilize GIP ELISA for detecting and quantifying this peptide in research studies.
Biological function summary

The GIP plays a significant role in stimulating insulin secretion in response to glucose intake which does not function alone. It works as part of the enteroinsular axis influencing nutrient uptake and metabolism. GIP also regulates fat metabolism by acting on adipocytes therefore playing a part in energy homeostasis. The exploration of GIP activity often involves MSD assay development to better understand its biological implications.

Pathways

The glucose-stimulated insulin secretion pathway incorporates GIP to enhance the release of insulin from the pancreas. It interacts with other proteins such as insulin and glucagon-like peptide-1 (GLP-1) to exert its glucose-lowering effects. GIP's involvement in the incretin pathway supports the body's maintenance of energy balance and glucose homeostasis under normal physiological conditions.

Glucose homeostasis dysfunction links GIP to type 2 diabetes and obesity. Impairments in GIP secretion or receptor signaling are associated with these metabolic disorders. Studies suggest that dysregulation of GIP along with related proteins like insulin can contribute to disease progression. By targeting GIP researchers at places like Abcam are looking for potential therapies to tackle these health challenges.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

Potent stimulator of insulin secretion and relatively poor inhibitor of gastric acid secretion.
See full target information Gastric inhibitory polypeptide
style
left-column

文献 (9)

Recent publications for all applications. Explore the full list and refine your search

Molecular and cellular biochemistry 478:2779-2787 PubMed36920577

2023

Individuals with type 2 diabetes have higher density of small intestinal neurotensin-expressing cells.

Applications

Unspecified application

Species

Unspecified reactive species

Filipa P Ferreira,Sofia S Pereira,Madalena M Costa,Marta Guimarães,Nicolai J Wewer Albrechtsen,Jens J Holst,Mário Nora,Mariana P Monteiro

Cell chemical biology 29:1368-1380.e5 PubMed35998625

2022

In vivo drug discovery for increasing incretin-expressing cells identifies DYRK inhibitors that reinforce the enteroendocrine system.

Applications

Unspecified application

Species

Unspecified reactive species

Lianhe Chu,Michishige Terasaki,Charlotte L Mattsson,Romain Teinturier,Jérémie Charbord,Ercument Dirice,Ka-Cheuk Liu,Michael G Miskelly,Qiao Zhou,Nils Wierup,Rohit N Kulkarni,Olov Andersson

Gastro hep advances 1:733-745 PubMed36117550

2022

FOXO1 Is Present in Stomach Epithelium and Determines Gastric Cell Distribution.

Applications

Unspecified application

Species

Unspecified reactive species

Wendy M McKimpson,Taiyi Kuo,Takumi Kitamoto,Sei Higuchi,Jason C Mills,Rebecca A Haeusler,Domenico Accili

Cell reports 38:110179 PubMed34986353

2022

Intestinal Gpr17 deficiency improves glucose metabolism by promoting GLP-1 secretion.

Applications

Unspecified application

Species

Unspecified reactive species

Shijun Yan,Jason M Conley,Austin M Reilly,Natalie D Stull,Surabhi D Abhyankar,Aaron C Ericsson,Tatsuyoshi Kono,Andrei I Molosh,Chandrashekhar A Kubal,Carmella Evans-Molina,Hongxia Ren

eLife 9: PubMed32410729

2020

Identification of novel, clinically correlated autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq.

Applications

Unspecified application

Species

Unspecified reactive species

Sara E Vazquez,Elise Mn Ferré,David W Scheel,Sara Sunshine,Brenda Miao,Caleigh Mandel-Brehm,Zoe Quandt,Alice Y Chan,Mickie Cheng,Michael German,Michail Lionakis,Joseph L DeRisi,Mark S Anderson

Journal of cellular biochemistry 119:7506-7514 PubMed29761876

2018

Differential GIP/GLP-1 intestinal cell distribution in diabetics' yields distinctive rearrangements depending on Roux-en-Y biliopancreatic limb length.

Applications

Unspecified application

Species

Unspecified reactive species

António M Palha,Sofia S Pereira,Madalena M Costa,Tiago Morais,André F Maia,Marta Guimarães,Mário Nora,Mariana P Monteiro

Experimental and therapeutic medicine 13:2558-2564 PubMed28565879

2017

Difference in protective effects of GIP and GLP-1 on endothelial cells according to cyclic adenosine monophosphate response.

Applications

Unspecified application

Species

Unspecified reactive species

Dong-Mee Lim,Keun-Young Park,Won-Min Hwang,Ju-Young Kim,Byung-Joon Kim

Critical care medicine 42:57-65 PubMed23963126

2013

The effects of critical illness on intestinal glucose sensing, transporters, and absorption.

Applications

Unspecified application

Species

Unspecified reactive species

Adam M Deane,Chris K Rayner,Alex Keeshan,Nada Cvijanovic,Zelia Marino,Nam Q Nguyen,Bridgette Chia,Matthew J Summers,Jennifer A Sim,Theresia van Beek,Marianne J Chapman,Michael Horowitz,Richard L Young

Diabetes 62:3532-41 PubMed23761104

2013

Disordered control of intestinal sweet taste receptor expression and glucose absorption in type 2 diabetes.

Applications

Unspecified application

Species

Human

Richard L Young,Bridgette Chia,Nicole J Isaacs,Jing Ma,Joan Khoo,Tongzhi Wu,Michael Horowitz,Christopher K Rayner
View all publications
style
left-column
style
left-column
style
right-column

代替製品

Primary Antibodies

AB25973

Anti-GIP antibody

Immunocytochemistry/ Immunofluorescence - Anti-GIP antibody (AB25973)

  • 4
  • 1
Primary Antibodies

AB48286

Biotin Anti-GIP antibody

  • 5
  • 1
Primary Antibodies

AB48134

Anti-GIP antibody

  • 5
  • 1
Primary Antibodies

AB271989

Anti-GIP antibody [EPR20410] - BSA and Azide free

BOND RX™ Validated|RabMAb|Advanced Validation|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GIP antibody [EPR20410] - BSA and Azide free (AB271989)

  • 0
  • 0
Primary Antibodies

AB223157

Anti-GIP antibody [EPR20410] - Low endotoxin, Azide free

Recombinant|Advanced Validation|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GIP antibody [EPR20410] - Low endotoxin, Azide free (AB223157)

  • 0
  • 0
Primary Antibodies

AB209792

Anti-GIP antibody [EPR20410]

BOND RX™ Validated|20ul selling size|RabMAb|Advanced Validation|Recombinant|Trial Size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GIP antibody [EPR20410] (AB209792)

  • 0
  • 0

組合せ製品

Assay Kits

AB102513

Adipogenesis Detection Assay Kit (Colorimetric/Fluorometric)

Functional Studies - Adipogenesis Detection Assay Kit (Colorimetric/Fluorometric) (AB102513)

  • 0
  • 0
Primary Antibodies

AB92517

Anti-Glucagon antibody [EP3070]

RabMAb|Recombinant|Lab Essentials|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Glucagon antibody [EP3070] (AB92517)

  • 5
  • 8
Primary Antibodies

AB181547

Anti-Insulin antibody [EPR17359]

BOND RX™ Validated|RabMAb|Recombinant|Lab Essentials|20ul selling size|Advanced Validation

Multiplex immunohistochemistry - Anti-Insulin antibody [EPR17359] (AB181547)

  • 5
  • 11
Primary Antibodies

AB131246

Anti-Peptide YY/PYY antibody

BOND RX™ Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Peptide YY/PYY antibody (AB131246)

  • 5
  • 5
Primary Antibodies

AB15580

Anti-Ki67 antibody

BOND RX™ Validated|KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Ki67 antibody (AB15580)

  • 5
  • 230

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com